Column Group III GP Boosts Surrozen Shares, Betting on Biotech Breakthroughs & Value‑Based Reimbursement
Column Group’s $250M stake in Surrozen (SZO) signals confidence that its biotech pipeline will thrive under value‑based care and next‑gen delivery tech, offering investors a potential upside once Phase III data arrive.
5 minutes to read